Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02351297
Other study ID # 2013-A01730-45
Secondary ID
Status Completed
Phase N/A
First received January 20, 2015
Last updated January 20, 2016
Start date January 2015
Est. completion date May 2015

Study information

Verified date January 2016
Source Hospital Avicenne
Contact n/a
Is FDA regulated No
Health authority France: Ethics Committee
Study type Interventional

Clinical Trial Summary

This study aims at evaluating the consequences of a 3 weeks high protein diet on the large intestine ecosystem (microbiota, metabolites and gene expression in rectal mucosa). Those parameters will be analysed with technics including OMICs methods. After a run-in period, 42 volunteers will receive either soy or milk protein or maltodextrin as a placebo control. This trial is double blind randomized placebo-controlled paralleled design (3 arms). Longitudinal sampling will allow the comparison of parameters during the study.


Description:

High protein diets are widely used for their slimming effect. Those diets increase the quantity of undigested protein and peptides reaching the large intestine. Microbiota utilizes protein and peptides as substrates and produces amino-acid derived metabolites such as short chain fatty acids, branched chain fatty acids, lactate, formate, succinate, ammonium, hydrogen sulfide and phenolic compounds. Some of those metabolites have been shown to be beneficial to the host whereas other could be deleterious. High protein diets may have different effects whether based on animal or plant proteins since those two kinds of protein have different amino acids composition and slightly different digestibility. The objective of this study is to evaluate in overweight volunteers the consequences of high protein diets (animal vs vegetal) vs isocaloric-normoproteic diet at the level of the large intestine and metabolism. Firstly, composition and activity of the microbiota and the metabolites produced in the large intestine lumen will be determined. Then, to evaluate the consequences of the tested diets on mucosal physiology, gene expression will be analyzed in rectal biopsies and fecal water will be tested on colonocytes cell lines. Lastly, the consequences of the diets on host metabolism will be evaluated.

Dietary intervention

Before the study, volunteers (n=42) will provide a 3 day food record that will be utilized by a dietician to calculate their usual energy intake. The study will start with a 2 weeks normalization period during which the volunteers will have to eat according to menus (Fig. 1). The diet will provide to the volunteer their usual individual energy intake; and protein, carbohydrates and fat will respectively provide 15, 50 and 35 % of the energy intake.

At the end of this standardization period, volunteers will be randomly assigned into 3 groups (n=14) for 3 weeks (intervention period) (Fig. 1). Volunteers of the 3 groups will follow a diet with a reduced digestible carbohydrates intake (15% of energy intake) while undigestible carbohydrate intake will remain unchanged. The volunteers will consume 3 times per day a dietary supplement powder that they will dissolve in water and then drink. This supplement will provide them 15% of their energy intake. The first group will receive a casein (animal protein) supplement so that they will have a high protein diet (protein, carbohydrates and fat will respectively provide 30, 35 and 35 % of the energy intake). The second group will receive a soy protein(vegetal) supplement so that they will also consume a high protein diet (protein, carbohydrates and fat will respectively provide 30, 35 and 35 % of the energy intake). The third group will receive a maltodextrin (digestible carbohydrate, placebo control) supplement so that they will ingest a normoproteic diet, similar in macronutrient composition to the standardization diet (protein, carbohydrates and fat will respectively provide 15, 50 and 35 % of the energy intake). The dietary supplement will be given in a double-blinded protocol. There will be no energy restriction between the standaridization and intervention periods.

Clinical protocol

Daily, the volunteers will measure their body weight and record their food consumption and physical activity. Once a week, they will have a phone call with a dietician to ensure dietary compliance (Fig. 2).

At the end of the normalization period, 13 days after the beginning of the study (D13), volunteers will collect 24h urine samples. Stool samples will be collected from the evening of D13 to the morning of D14 . A cooler will be provided to the volunteer for storage and transport of samples. After one night fasting, in the morning of D14, the volunteers will come to the hospital and will bring their samples that will be immediately conditioned for storage. Blood samples will be collected. Then, rectal biopsies will be recovered. Every week during the intervention period, urine stool and blood will be sampled (D21, D28, D35). At the end of the intervention period, rectal biopsies will be recovered (D35). Body weight and blood pressure will be measured at each visit.

Analyses All measured parameters will be expressed relatively to baseline.

Dietary intake will be evaluated by dietician based on food records.

Stool samples

- Microbiota composition and functions

- Luminal metabolites composition

- pH, osmolarity, water content

- Fecal water test on HT-29 cells (colonocytes) for mitochondrial respiration, proliferation, genotoxicity, cytotoxicity, gene expression

Urines

- Urea and creatinine assay (protein consumption marker to verify dietary compliance)

- Metabolomics

Blood

- Clinical parameters (total cholesterol, LDL and HDL cholesterol, non-esterified fatty acids, triglycerides, glycemia, insulinemia)

- Metabolomics

Rectal biopsies

• Transcriptomic analyses


Recruitment information / eligibility

Status Completed
Enrollment 42
Est. completion date May 2015
Est. primary completion date May 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 45 Years
Eligibility Inclusion Criteria:

- BMI 25- 30

- Body weight stable last 3 months

- Moderate physical activity

Exclusion Criteria:

- Abnormal food behavior

- Digestive, renal, hepatic, pulmonary, hemostasis, neoplasic diseases

- antibiotic, pre or probiotics use in the last 3 months

- intolerance for the tested product

- positive serology for infectious disease

- pregnancy

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
casein supplementation
After the run-in period, volunteers will receive casein supplementation (15 % of energy intake) for 3 weeks.
soy protein supplementation
After the run-in period, volunteers will receive soy protein supplementation (15 % of energy intake) for 3 weeks.
maltodextrin supplementation
After the run-in period, volunteers will receive maltodextrin supplementation (15 % of energy intake) for 3 weeks.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Hospital Avicenne

Outcome

Type Measure Description Time frame Safety issue
Primary Change in gene expression in rectal biopsy from baseline after 3 week dietary intervention Gene expression in biopsies collected before (baseline) and after 3 week dietary intervention will be measured by transcriptomic analyses. Differential gene expression will be expressed as relative units (fold change). Change for baseline in gene expression in rectal biopsy after 3 weeks dietary intervention No
Secondary microbiota composition analysis Microbiota composition will be analysed in stool samples before (baseline) and after 3 week dietary intervention using metagenomic analyses and will be expressed as bacterial relative abundance. Change for baseline in microbiota composition after 3 weeks dietary intervention No
Secondary fecal water metabolomics Fecal water metabolites will be analysed in stool samples before (baseline) and after 3 week dietary intervention using RMN analyses and will be expressed as metabolites relative abundance. Change for baseline in fecal water metabolites after 3 weeks dietary intervention No
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1